NeuBase Therapeutics, Inc.: restructuring charge — NeuBase halts program development, cuts 83% workforce, explores strategic alternatives

NeuBase Therapeutics, Inc.

Workforce reduced by ~83%; estimated $400K in severance and termination costs.
Board halts further development of all programs, including Stealth Editors gene editing candidates.
Company will explore strategic alternatives: acquisition, merger, business combination, or other transaction.
No timetable set for evaluation; no assurance that any transaction will be completed.
Decision not related to safety issues or negative regulatory feedback; cost-cutting focus.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

NeuBase Therapeutics, Inc. announced a restructuring with charges of approximately $400,000 affecting different areas and functions (approximately 83%).

Type: restructuring
Charge: approximately $400,000
Affected area: different areas and functions
Headcount: approximately 83%

Exact text from the filing

compensation grants and continuation of group health insurance coverage for a specified period to the affected employees. The Company estimates that it will incur approximately $400,000 of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The costs related to the Restructuring are subject to a

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001558370-23-013051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.